Nolomirole HCl | CAS#138531-51-8 | Dopamine Receptor Agonist

MedKoo Cat#: 525765 | Name: Nolomirole HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nolomirole HCl is a Dopamine Receptor Agonist. Nolomirole is able to attenuate the heart failure signs in the monocrotaline-induced congestive heart failure.

Chemical Structure

Nolomirole HCl

CAS#138531-51-8

Theoretical Analysis

MedKoo Cat#: 525765

Name: Nolomirole HCl

CAS#: 138531-51-8

Chemical Formula: C19H28ClNO4

Exact Mass: 369.1707

Molecular Weight: 369.89

Elemental Analysis: C, 61.70; H, 7.63; Cl, 9.58; N, 3.79; O, 17.30

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

CHF1035; CHF-1035; CHF 1035; Nolomirole Hydrochloride; Nolomirole HCl

IUPAC/Chemical Name

6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diyl bis(2-methylpropanoate) hydrochloride

InChi Key

TWTMQRXNAZGSCE-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H27NO4.ClH/c1-11(2)18(21)23-16-9-6-13-10-14(20-5)7-8-15(13)17(16)24-19(22)12(3)4;/h6,9,11-12,14,20H,7-8,10H2,1-5H3;1H

SMILES Code

CNC1CC2=CC=C(OC(C(C)C)=O)C(OC(C(C)C)=O)=C2CC1.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 369.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Andersson C, Gislason GH, Weeke P, Kjaergaard J, Hassager C, Akkan D, Møller JE, Køber L, Torp-Pedersen C; EchoCardiography and Heart Outcome Study (ECHOS) investigators. The prognostic importance of a history of hypertension in patients with symptomatic heart failure is substantially worsened by a short mitral inflow deceleration time. BMC Cardiovasc Disord. 2012 Apr 25;12:30. doi: 10.1186/1471-2261-12-30. PubMed PMID: 22533520; PubMed Central PMCID: PMC3470965. 2: Torp-Pedersen C, Køber L, Carlsen JE, Akkan D, Bruun NE, Dacoronias D, Dickstein K, Haghfelt T, Ohlin H, McMurray JJ. A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail. 2008 Jan;10(1):89-95. doi: 10.1016/j.ejheart.2007.10.012. Epub 2007 Dec 27. PubMed PMID: 18164245. 3: Kjaergaard J, Akkan D, Iversen KK, Køber L, Torp-Pedersen C, Hassager C. Right ventricular dysfunction as an independent predictor of short- and long-term mortality in patients with heart failure. Eur J Heart Fail. 2007 Jun-Jul;9(6-7):610-6. Epub 2007 Apr 25. PubMed PMID: 17462946. 4: Cleland JG, Coletta AP, Clark AL, Velavan P, Ingle L. Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: darbepoetin alfa study, ECHOS, and ASCOT-BPLA. Eur J Heart Fail. 2005 Aug;7(5):937-9. PubMed PMID: 16048744. 5: Pasini E, Cargnioni A, Pastore F, Razzetti R, Bongrani S, Gitti GL, Ferrari R. Effect of nolomirole on monocrotaline-induced heart failure. Pharmacol Res. 2004 Jan;49(1):1-5. PubMed PMID: 14597145. 6: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Sep;25(7):565-97. PubMed PMID: 14571286. 7: Savolainen J, Rautio J, Razzetti R, Järvinen T. A novel D2-dopaminergic and alpha2-adrenoceptor receptor agonist induces substantial and prolonged IOP decrease in normotensive rabbits. J Pharm Pharmacol. 2003 Jun;55(6):789-94. PubMed PMID: 12841939. 8: Taddei P, Torreggiani A, Fini G. Vibrational study of polymorphism of tetralin derivative for treatment of cardiovascular diseases. Biopolymers. 2002;67(4-5):289-93. PubMed PMID: 12012450. 9: Tjeerdsma G, van Wijk LM, Molhoek GP, Boomsma F, Haaksma J, van Veldhuisen DJ. Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. Cardiovasc Drugs Ther. 2001 Mar;15(2):139-45. Erratum in: Cardiovasc Drugs Ther 2002 Jan;16(1):79. PubMed PMID: 11669407. 10: Giordano F, Rossi A, Moyano JR, Gazzaniga A, Massarotti V, Bini M, Capsoni D, Peveri T, Redenti E, Carima L, Dagli Alberi M, Zanol M. Polymorphism of rac-5,6-diisobutyryloxy-2-methylamino-1,2,3,4-tetrahydro-naphthalene hydrochloride (CHF 1035). I. Thermal, spectroscopic, and X-ray diffraction properties. J Pharm Sci. 2001 Aug;90(8):1154-63. Erratum in: J Pharm Sci. 2002 Nov;91(11):2466. PubMed PMID: 11536220.